Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

British industry leaders fear tariffs imposed by President Trump could disrupt the supply and even the price of drugs ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Trump’s latest tariff vow threatens to disrupt supplies of obesity drugs such as Mounjaro and Wegovy as pharma giants face ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.